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status of the donor and recipient. [6, 7] Seropositivity is used as a marker for exposure in donors and recipients. CMV immunoglobulin G (IgG) is the standard tool for pre-Tx assessment of serological status in donor and recipient. There is a paucity of literature regarding the influence of pre-Tx CMV IgG antibodies levels (pre-Tx IgG) on the post-Tx CMV reactivations/infection. [8] [9] [10] Objective This prospective study was done to investigate the incidence and timeline of CMV infection in seropositive liver transplant (LTx) recipients and correlate the risk of infection with pre-Tx IgG levels.
mateRIals and methods

Study population and design
All patients who underwent LTx at the Institute of Liver and Biliary Sciences from March 2012 to April 2015 were included in this prospective study. Exclusion criteria consisted of patients who received simultaneous other organ transplant, patients not on immunosuppression, recipients of organs from cadaveric donors and patients who were unwilling to participate in the study. The study was approved by the Institutional Ethical Review board. Pre-Tx blood samples were collected from all the recipients and their respective donors for CMV IgG determination. After the transplant, all the recipients were followed up weekly for a month and later monthly for 1 year post-Tx by CMV DNA polymerase chain reaction (PCR), for the presence of an active CMV infection. CMV disease was diagnosed and defined as per recommendations. [4] CMV DNA positivity in blood (DNAemia) was considered as the evidence of CMV infection. CMV disease i.e., CMV infection with attributable symptoms was further categorised as: CMV syndrome (fever, malaise, leucopenia and/or thrombocytopenia) and CMV tissue-invasive disease (detection of CMV in the tissue specimen).
Treatment and follow-up
All patients received triple regimen immunosuppression (tacrolimus + mycophenolate mofetil + steroid). The trough level of tacrolimus was maintained at 5-10 ng/ml. Steroids were tapered in majority by the end of 3 months. Recipients were not on anti-CMV prophylaxis. Patients were clinically examined for signs and symptoms of CMV infection every month. Patients were given pre-emptive treatment if the CMV viral load was ≥500 copies/ml regardless of clinical manifestations as per the Institute's protocol. Pre-emptive therapy consisted of intravenous ganciclovir (5 mg/kg, 12 hourly) or oral valganciclovir (900 mg twice daily) until the patient became negative by CMV DNA PCR. Therapy was stopped once two consecutive samples taken 2 weeks apart were negative for CMV DNA.
Immunoglobulin G antibody to cytomegalovirus
Quantitative determination of IgG antibodies to CMV in plasma was done by the Architect CMV IgG assay (Abbott Laboratories, Chicago, IL, USA) which is a chemiluminescent microparticle immunoassay as per the manufacturer's instructions. The cut-off values were calculated based on each individual run to determine each sample as reactive or non-reactive. Results were expressed as AU/ml. Samples with concentration values ≥6.0 AU/mL were considered reactive for IgG antibodies to CMV. The assay calculated the results till 250 AU/ml and samples with values ≥250 AU/ml were reported as ≥250 AU/ml. To analyse all the patients, we characterised the study population in two groups: patients with titres ≥250 AU/ml and those with titres <250 AU/ml. This value provided the best sample size balance for result analysis.
Cytomegalovirus DNA polymerase chain reaction
Quantitative real-time PCR for CMV was performed by LightMix ® Kit on Roche Light cycler 480 Instrument (Roche Diagnostics, Manheim, Germany) in accordance with the manufacturer's instructions. This assay targets viral glycoprotein gene, 226 bp in size using Light DNA master hybridisation probe. Results were expressed as copies of virus/ml plasma. The linear range of the test is 10 2 copies to 10 6 copies/ml. Lower limit of detection of the assay is 500 copies. Samples with values ≥500 copies/ml were reported in exact copies/ml and others as <500 copies/ml.
Statistical analysis
Statistical analysis was done using SPSS version 20 (SPSS Inc., Chicago, IL, USA). Quantitative variables were expressed as median with interquartile ranges (IQRs), and qualitative variables as percentages. P < 0.05 was considered statistically significant. Numerical data were calculated using Microsoft Excel and analyzed. The cumulative incidence of CMV reactivation after transplant with respect to pre-transplant CMV titre was estimated with Kaplan-Meier methodology. A univariate cox proportional hazard model was used to estimate the risk of CMV infection after Tx and its association with various variables.
Results
Characteristics of the study population
Overall, 155 LTx and their respective donors were enrolled in the study. Nine recipients died during the 1-year follow-up; hence they were excluded from the study. The final analysis included 146 patients (132 adults and 14 paediatric patients) [ Table 1 ]. Mean age of the paediatric patients was 5.9 (range: 2-12) years and none were <12 months of age. The pre-Tx recipient (R) seropositivity in the study group was 100% whereas both donor (D) and recipient seropositive status (D+/R+) was 97% in adults and 100% in the paediatric population. None were in the category of high-risk group i.e., D+/R−. In the study group, out of the various causes, the most common aetiology for end-stage liver disease was cryptogenic liver disease (33%) followed by alcoholic liver disease (22.5%) [ Table 2 ].
Post-transplant cytomegalovirus infection
Post-Tx CMV DNA positivity in blood (DNAemia) was considered as the evidence of CMV infection. Out of 146 LTx recipients, post-Tx CMV infection was seen in 54 (36.9%) recipients consisting of 60 episodes. Median CMV viral load was 3.5 log10 (R: 2.5-6.6 log10) copies/ml. Forty-five (29%) recipients had a CMV viral load of ≥500 copies/ml. In 14 (9.5%) patients, demonstrable CMV disease was seen, none of the recipients developed CMV invasive disease based on negative histopathology and immunohistochemistry markers in tissue biopsy specific for CMV infection. CMV infections with viral load of ≥500 copies/ml were successfully treated with ganciclovir/valganciclovir. No evidence of clinical drug resistance was recorded as all responded to the treatment and cleared off the infection. Clearance of CMV from blood in them was seen in a median time of 6.4 days (IQR: 2.4-13 days) of therapy. Post-Tx occurrence of CMV infection was higher in paediatric patients (10 [71.4%]) than adults (44 [31.2%]) (P = 0.004).
Timing of cytomegalovirus infection
On estimating the time of occurrence of CMV infection after Tx, maximum number of infections 32 (59.2%) were seen in the 1 st month followed by 13 (24%) infections in the 2 nd month [ Table 3 ]. Median time of occurrence of CMV was 22 days (IQR, 10.5-48 days). There was a significant difference in the time of occurrence of CMV infection between adult and paediatric patients. Time of occurrence was earlier in children than adults (13.4 ± 6.9 vs. 42.4 ± 3 days, respectively, P = 0.001).
Pre-transplant cytomegalovirus immunoglobulin G titres and cytomegalovirus infection
Pre-Tx IgG levels of the recipients were measured before transplantation. A total of 113 (77.4%) had titres ≥250 AU/ml while the remaining 33 (22.6%) had titres <250 AU/ml. Post-Tx CMV infection rates among those with pre-Tx IgG < 250 AU/mL and ≥250 AU/mL were 42.4% and 34.5% (P = 0.99), respectively. Post-Tx CMV viral load in patients with titre <250 AU/ml was significantly higher, median value was 4.0 log10 (R: 2.8-6.6 log10) copies/ml than in those with titres ≥250 AU/ ml: median value was 2.2 log10 (R: 1.6-3.8 log10) copies/ml, P = 0.04. However, on comparing the two groups in the time of occurrence of the CMV infection, we found no difference in both the groups [ Figure 1 , P = 0.81, log-rank test].
Other risk factors associated with cytomegalovirus infection
In a univariate analysis, various factors such as age of the recipient, sex and pre-Tx IgG titres were evaluated for their association with the occurrence of CMV infection after Tx, but none of the variables were found to have any significant association with an increased risk of CMV infection.
Rejection and cytomegalovirus infection
Histopathological evidence of acute rejection was seen in 30 (19.5%) recipients. Concurrent occurrence of rejection along with CMV infection was seen in significantly more patients 18/54 (32.7%) than in patients without CMV infection (12/99, 12%, P = 0.002). All the rejection episodes were successfully treated with steroids and optimisation of immunosuppression.
dIscussIon
The present study explores a very important arm of CMV immunity i.e., CMV-specific humoral immune responses in the transplant settings. Following primary CMV infection, both cellular and humoral immune responses are activated. [11] Sustained control of CMV infection is largely accounted for by cellular immunity, involving various T-cell and B-cell subsets, but humoral responses also interplay between the various host factors contributing to the reactivation of CMV. The role of antibodies in the protection and control of CMV has been debated. [12] Limited literature available across various SOTs favours that CMV IgG antibody titres may have a role in restricting viral dissemination and probably might contribute to minimising the clinical manifestations of the disease, but it has been studied less frequently. [13] [14] [15] [16] The present study was done on the cohort of LTx recipients who were 100% seropositive to CMV prior to transplant. We studied their pre-Tx CMV IgG titres and its relation to post-Tx occurrence of CMV infection. We found slight increase in the risk of CMV infection in recipients with less pre-Tx titre of CMV IgG, but it was not statistically significant. A similar study done on a very large cohort of seropositive liver Tx recipients had shown a significant association of lower Pre-Tx CMV titres and post-Tx occurrence of CMV infection. [6] Our study demonstrated that post-Tx severity of CMV infection as depicted by CMV viral load was significantly higher in the group that had lower pre-Tx IgG levels, thereby emphasising the role of Pre-Tx CMV IgG estimation. Pre-Tx titre could help in deciding the group of patients to be considered for prophylaxis or in initiation of pre-emptive treatment to prevent further severe CMV infections.
The incidence of post-Tx CMV infection seen in our study is very much in agreement with the published literature but slightly higher from a previously published study from this part of our country. [17] This could be due to the increased sensitivity and specificity of the detection assay used. [2, 18] Variability of CMV viral load testing across laboratories has shown the inconsistency in viral load values for individual samples ranging from 2.0 to 4.3 log10 copies/ml. [19] This may be due to lack of an international reference standard and variation in the assay design. However, now World Health Organization's international reference standard is available to overcome this problem of variability in CMV DNA testing. [20] Time line of CMV infections in transplant recipients is usually thought to be from 2 nd to 4 th month after transplant, and is dependent on factors such as levels of immunosuppression and prophylaxis given. [6, 21] There is a clear shift in the timeline of CMV infection seen in the present study with most of the infections seen in the 1 st month post-Tx, especially in the 2 nd and 3 rd weeks post-Tx. The consensus guidelines on timing of CMV monitoring post-Tx are missing and most centres adapt to CMV DNA PCR screening only after the 1 st month of transplant, hence may be missing out some of the important infections. [4] A high incidence of CMV infection, especially in the paediatric age group, was seen in our study. Another important observation seen in the present study was paediatric CMV reactivations were earlier and more, as compared to adult patients. Colonisation of CMV starts very early in life due to a relatively more immunodeficit state. [22, 23] In the present study, all the CMV infections were seen during the 1 st post-Tx month unlike in adults. This highlights the significance of early screening for CMV in paediatric recipients of SOT. Another observation of the present study is that post-Tx CMV infection also increases the risk of rejection of the transplanted organ. It is known that CMV infection through its various direct and indirect effects posed by CMV DNAemia in the recipients mileu leads to a cascade of reactions affecting the graft survival. [24] Although our data are very limited, they highlight the association of CMV infection to rejection.
The preliminary results presented in our study might be the first step to study CMV humoral responses in a more specific way. A large prospective study with a standardised methodology in multiorgan transplant should be conducted to confirm the results observed in our study.
conclusIons
Pre-Tx CMV IgG titres might influence the course of post-Tx CMV infections. Higher pre-Tx CMV IgG levels might prevent severe CMV infections post-Tx. Recipients with low pre-Tx CMV titre might be benefitted by CMV prophylaxis or aggressive pre-emptive treatment. 
